Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial

BACKGROUND: The benefit of systemic treatments in esophageal squamous cell carcinoma (ESCC) which has progressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established. We aimed to compare the efficacy of irinotecan plus S-1 with S-1 monot...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jing, Xu, Binghe, Liu, Ying, Huang, Junxing, Lu, Ping, Ba, Yi, Wu, Lin, Bai, Yuxian, Zhang, Shu, Feng, Jifeng, Cheng, Ying, Li, Jie, Wen, Lu, Yuan, Xianglin, Ma, Changwu, Hu, Chunhong, Fan, Qingxia, Wang, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444575/
https://www.ncbi.nlm.nih.gov/pubmed/30940189
http://dx.doi.org/10.1186/s40880-019-0359-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444575/
https://www.ncbi.nlm.nih.gov/pubmed/30940189
http://dx.doi.org/10.1186/s40880-019-0359-7

Ejemplares similares